Firm will also leverage funding to progress other Immunodrug candidates in its pipeline.
Focus will be on early-stage firms in Europe, but fund will also consider the U.S.
One-year clinical trial data indicates that MSC infusions are safer than immunosuppressants.
IRES technology will be used in the development of mouse models.
Firm plans to generate a global business through acquisitions and licensing deals.
Team finds dual strategy removes cell cycle checkpoints and results in DNA-damaged cancer cells undergoing apoptosis.
View more news updated daily on the GEN website.
Supreme Court Unanimously Overturns Prometheus Dosage Calibration Method Patent March 20, 2012, 12:52 PM EDT
Big Pharma Saw an Almost One-Third Drop in Patent Filings Between 2007 and 2009 March 20, 2012, 10:58 AM EDT
|
